NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease.

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband isn't sure if it made a difference.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

For Eisai and Biogen, the CHMP’s decision to stick by its previous call now punts the final approval verdict for Leqembi back to the European Commission (EC), which is the ultimate authority on ...

NEW YORK – The European Commission will resume its review of Eisai and Biogen's marketing authorization application for their anti-amyloid Alzheimer's disease drug Leqembi (lecanemab), the companies ...

The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that ...

Both Kisunla and the other approved drug, Leqembi, have been shown to slow down the mental decline of Alzheimer's by more than 25%. But that's in a group of patients—an individual may do much ...

Both Kisunla and the other approved drug, Leqembi, have been shown to slow down the mental decline of Alzheimer's by more than 25%. But that's in a group of patients—an individual may do much better, ...